Topline data were announced from two phase 3 trials evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...

Topline data were announced from two phase 3 studies evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

Viatris (NASDAQ:VTRS) stock rises 5% premarket as Phase 3 trials show success for non-opioid pain therapy, meloxicam as a ...

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

Viatris' fast-acting form of generic pain drug meloxicam met the main goals of two late-stage studies, the company said on Thursday, adding that it would seek the US FDA's marketing approval for the ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Viatris Inc (NASDAQ:VTRS) announced positive data for Phase 3 studies of novel fast-acting meloxicam for moderate to severe acute pain, highlighting its potential as a non-opioid treatment option. The ...